E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Advanced breast cancer (stage IIIB/IIIC/IV) and confirmed BRCA+ status
Cáncer de mama avanzado (estadíos IIIB/IIIC/IV) y con estado BRCA+ confirmado |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10006187 |
E.1.2 | Term | Breast cancer |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of KU-0059436 in terms of objective tumour response rate when administered orally to patients with advanced BRCA1- or BRCA2-associated breast cancer. |
|
E.2.2 | Secondary objectives of the trial |
- To assess the efficacy of KU-0059436 in terms of clinical benefit rate (complete response [CR] and partial response [PR] and stable disease [SD]) at various timepoints and time to disease progression (TTP) when administered orally to patients with advanced BRCA1- or BRCA2 associated breast cancer.
- To investigate the pharmacodynamic profile of KU-0059436 in PBMCs.
- To assess the safety & tolerability profile of KU-0059436 when administered orally to patients with advanced BRCA1- or BRCA2-associated breast cancer.
- To determine exposure to KU-0059436 following oral administration to patients with advanced BRCA1- or BRCA2-associated breast cancer.
For exploratory objectives please refer to study protocol (protocol synopsis and overall design).
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
To be eligible for inclusion into this study, each patient must fulfil the following inclusion criteria within 28 days prior to Study Day 1, as defined in Section 5 of the protocol:
1. Female, aged 18 years or older.
2. Histologically or cytologically confirmed breast cancer that is locally advanced (not amenable to curative surgery and/or radiation) or has metastasised (Stage IIIB/IIIC or IV, respectively, according to the American Joint Committee on Cancer Criteria). Patients with spinal cord compression may be considered if they have received definitive treatment for this and evidence of clinically stable disease for at least 28 days.
3. Confirmed BRCA1 or BRCA2 status (with a pre-existing genetic report & sequence scan). Please note: if there is a strong family history and evidence suggesting BRCA-/- status, then patients may be screened for the study, but must not receive IMP until a confirmatory Myriad Genetics sequence report is received.
4. One or more measurable lesions, at least 10 mm in the longest diameter (LD) by spiral CT scan, or 20 mm with conventional techniques, according to RECIST criteria, not irradiated within 12 weeks of the first administration of IMP.
5. ECOG performance status of 0 – 2.
6. Estimated life expectancy of at least 16 weeks.
7. Failed at least one prior chemotherapy and/or endocrine therapy, and for whom, in the opinion of the Investigator, no curative standard therapy exists. Patients whose tumours are histologically Estrogen Receptor positive (ER+) and/or Progesterone Receptor positive (PR+) must have had at least one line of hormonal therapy, for which there will have to be a washout period of at least 28 days prior to trial entry.
8. Adequate bone marrow, hepatic and renal function, defined as: • Haemoglobin >= 9.0 g/dL, • White blood cells > 3x10e9/L, • Absolute neutrophil count >= 1.5x10e9/L, • Platelets >=100x10e9/L, • Total bilirubin <= 1.5 x upper limit of normal (ULN), • Aspartate transaminase (AST) (SGOT) and alanine transaminase (ALT) (SGPT) <= 2.5 x ULN (or ≤ 5 x ULN in the presence of liver metastases), • Serum creatinine <= 1.5 x ULN.
9. The patient is willing and able to comply with the protocol for the duration of the study, including undergoing treatment and scheduled visits and examinations.
10. The patient has given written informed consent prior to any study-related procedure not constituting part of the standard care for the condition, with the understanding that said consent may be withdrawn at any time, without prejudice to any future medical care.
|
|
E.4 | Principal exclusion criteria |
To be eligible for inclusion into this study, each patient must violate none of the following exclusion criteria within 28 days prior to Study Day 1, as defined in Section 5 of the protocl:
1. Less than 28 days from active therapy (i.e. any treatment used to treat the disease) or high dose radiotherapy (patients may continue concomitant use of bisphosphonates if used for at least 28 days prior to commencing study treatment and patients may receive palliative radiotherapy for bone disease during the study).
2. Patients who have been previously treated with inhibitors or inducers of the cytochrome P450 isozyme family, must have completed treatment at least 4 weeks prior to the first administration of IMP (unless otherwise stated as less in Section 3.5.1 of the protocol). In the case of fluoxetine and phenobarbitone, 5 weeks must have elapsed prior to the first administration of IMP.
3. Patients with brain metastases.
4. Any other malignancy which has been active or treated within the past 5 years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and non-melanoma skin lesions.
5. Persistent grade 2 or greater toxicities (excluding alopecia) from any cause.
6. Patients currently experiencing seizures or who are currently treated with any anti-epileptic.
7. Major thoracic and/or abdominal surgery in the four weeks prior to the start of study treatment.
8. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.
9. Presence of gastrointestinal disorders that, in the Investigator’s opinion, are likely to interfere with the absorption of the IMP.
10. Patients who are unable to swallow orally administered medication.
11. Patients who are immunocompromised, e.g. patients known to be serologically positive for human immunodeficiency virus (HIV).
12. Pregnant or breast-feeding women, or women of childbearing potential unless effective methods of contraception are used (lack of childbearing potential is met by being postmenopausal, being surgically sterile, practising contraception with an oral contraceptive or other hormonal therapy [e.g. hormone implants], intra-uterine device, diaphragm with spermicide or condom with spermicide, or being sexually inactive. Patients and their partners must agree to use one of the above forms of contraception throughout the treatment period and for 3 months after discontinuation of treatment).
13. Simultaneous participation in any other study involving an IMP, or having participated in a study less than 28 days prior to the start of study treatment.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
To assess the Objective Tumour Response Rate (proportion of patients with tumour response of CR + PR) of KU-0059436 after 4 cycles of treatment when administered orally to patients with advanced BRCA1 and BRCA2-associated breast cancer. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 11 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |